Procedura selettiva di chiamata per n. 1 posto di Ricercatore a tempo determinato - Tipologia B presso il Dipartimento di Chimica Tecnologie del Farmaco, Facoltà di Farmacia e Medicina, Settore Scientifico-disciplinare CHIM/08, Settore concorsuale 03/D1 di cui al bando emanato con D.R. n. 1828/2018 del 12/07/2018 con avviso pubblicato sulla G.U. – IV serie speciale n. 60 in data 31/07/2018, codice concorso 2018RTDB014.

GIOVANNA POCE
Curriculum Vitae

Roma
06/08/18

Part I – General Information

Full Name	Giovanna Poce
Date of Birth	
Place of Birth	
Citizenship	
Permanent Address	
Mobile Phone Number	
E-mail	
Spoken Languages	Italian (mother tongue); English (proficient user/C1)

Part II – Education

Type	Year	Institution	Degree
Ph.D.	10/03/2008	Faculty of Pharmacy, Sapienza University of Rome	Ph.D. in Pharmaceutical Sciences. Thesis title: "New Pyrrole Derivatives of BM212: a New Class of Antimycobacterial Agents. Design, Synthesis, Biological Evaluation and Study of their Mode of Action."
University graduation	18/03/2004	Faculty of Pharmacy, Sapienza University of Rome	Master Degree in Pharmaceutical Chemistry and Technologies. Thesis Title: "Sintesi e relazioni struttura attività di nuovi 1,5-diarilpirroli correlati al BM212."
Licensure	21/12/2004	Faculty of Pharmacy, Sapienza University of Rome	Licensed Pharmacist

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
01/10/2014	present	Department of Chemistry and Technology of Drugs, Sapienza University of Rome	RTD A) in Medicinal chemistry (CHIM/08)
01/10/2013	30/09/2014	Department of Chemistry and Technology of Drugs, Sapienza University of Rome	Research assistant
01/01/2013	30/09/2013	Department of Chemistry and Technology of Drugs, Sapienza University of Rome	Post-doc
02/01/2009	03/01/2013	Department of Chemistry and Technology of Drugs, Sapienza University of Rome	Research assistant

07/11/2007	07/11/2008	Department of Chemistry and Technology of Drugs, Sapienza University of Rome	Research fellow
01/11/2004	30/10/2007	Faculty of Pharmacy, Sapienza University of Rome	Ph.D. student

IIIB – Other Academic Appointments

Start	End	Institution	Position
03/08/2016	30/08/2016	Faculty of Health Sciences, University of Cape Town, South Africa.	Visiting Academic, group of Professor Musa Mhlanga
20/10/2010	30/08/2012	Department of Immunology and Infectious Diseases, Harvard School of Public Health, USA.	Visiting Scientist, group of Professor Eric J. Rubin
06/04/2009	30/10/2009	Department of Chemistry, Oxford University, UK.	Academic Visitor, group of Professor Steve G. Davies.

IIIC – Other Titles

Start	End	Institution	Position
21/01/2015	21/01/2021	MIUR: ASN	Appointed Associated Professor in Medicinal chemistry (Abilitazione Scientifica Nazionale, Professore II fascia, 03/D1 CHIM/08)

Part IV – Teaching experience

Year	Institution	Course
03/2015-present	Faculty of Pharmacy and Medicine, Sapienza University of Rome	Drug Analysis I, Pharmacy course.
10/2008-05/2014	Faculty of Pharmacy, Sapienza University of Rome	Teaching assistant in practical course of Drug Analysis II, Pharmacy course.
2009-2016	Faculty of Chemistry, Sapienza University of Rome	Teaching II level master “Sostanze Organiche e Naturali”.

Part V - Society memberberships

Year	Title
2004-present	Member of the Italian Chemical Society (SCI)

Part VI - Funding Information [grants as PI-principal investigator, PL-project leader or I-investigator]

Year	Title	Program/role	Grant value
2018	Novel MmpL3 inhibitors-loaded niosomes to treat tuberculosis via lung delivery	Progetto di Ricerca di Università, Università degli studi di Roma "La Sapienza". **I**	30000 €
2017	Finanziamento delle attività base di ricerca	Finanziamento delle attività base di ricerca. **PI**	3000 €
2017	Novel MmpL3 inhibitors to treat tuberculosis	Progetto di Ricerca di Università, Università degli studi di Roma "La Sapienza". **I**	20000 €
2016	Targeting tryptophan biosynthesis to treat tuberculosis	Ricerca Scientifica - Anno 2015. Finanziamento Medi Progetti Universitari, Università degli studi di Roma "La Sapienza". **PI**	8000 €
2015	Nuovi derivati del BM635, potente composto ad attività anti-tubercolare	Progetto di Ricerca di Università, Università degli studi di Roma "La Sapienza". **I**	10000 €
2012-2014	Hit-to-lead development for a new class of antimycobacterial agents.	Tres Cantos Open Lab Foundation (GSK, Madrid). **PL**	134000 €
2012	Validazione del target molecolare del BM212, hit compound di una nuova classe di composti a potente azione antimicobatterica.	Progetti per Avvio alla Ricerca, Università degli studi di Roma "La Sapienza". **PI**	2000 €
2011	Nuovi derivati 1,5-difenil pirrolici ad attività antitubercolare.	Progetto di Ricerca di Università, degli studi di Roma "La Sapienza". **I**	12000 €

2010	Derivati pirrolici del BM212: una nuova classe di composti ad attività antimicobatterica. Progettazione, sintesi, valutazione biologica e studio del loro meccanismo d'azione.	Progetto di Ricerca di Università, Università degli studi di Roma "La Sapienza". **I**	12000 €
2009-2012	New pyrrole derivatives of BM 212: a new class of antimycobacterial agents. Design, synthesis, biological evaluation and study of their mode of action.	Istituto Pasteur-Fondazione Cenci-Bolognetti. **I**	60000 €
2009	Progettazione, sintesi, valutazione microbiologica e studio del meccanismo di azione di nuovi derivati del BM212, potente agente antitubercolare a struttura pirrolica.	Progetto di Ricerca di Università, Università degli studi di Roma "La Sapienza". **I**	27600 €
2008	Progettazione, sintesi, valutazione microbiologica, studi di farmacocinetica e di biodisponibilità e del meccanismo di azione di nuovi derivati del BM212, agente antitubercolare a struttura pirrolica.	Progetto di Ricerca di Università, Università degli studi di Roma "La Sapienza". **I**	11000 €
2007	Nuovi derivati del BM212, agenti antitubercolari a struttura pirrolica: loro progettazione, sintesi, valutazione microbiologica, studi di farmacocinetica e di biodisponibilità e del meccanismo di azione.	Progetto di Ricerca di Università, Università degli studi di Roma "La Sapienza". **I**	26600 €
2006-2008	Sviluppo e caratterizzazione di nuovi farmaci antitubercolari con approcci chimico-informatici, microbiologici, molecolari e proteomici.	Fondazione CARIPLO. **I**	85610 €
2006	Nuovi agenti antitubercolari a struttura pirrolica, derivati del BM 212: loro progettazione, sintesi, valutazione microbiologica, studi di farmacocinetica e di biodisponibilità e del meccanismo di azione.	Ricerca di Ateneo, Università degli studi di Roma "La Sapienza". **I**	29600 €
2005	Progettazione, sintesi, valutazione microbiologica e studio del meccanismo di azione di nuovi agenti antitubercolari a struttura pirrolica, derivati del BM 212.	Ricerca di Ateneo, Università degli studi di Roma "La Sapienza". **I**	9000 €

2005-2007	Sviluppo di nuovi farmaci antitubercolari, valutazione della loro attività antimicobatterica e identificazione del bersaglio cellulare.	PRIN. **I**	57000 €

Part VII – Research Activities

Keywords	Brief Description
Tuberculosis, Medicinal chemistry	Design, synthesis and characterization of small molecules active against *M. tuberculosis* hitting novel targets: MmpL3, iron chelation, tryptophan biosynthetic pathway. Hit-to-Lead development.
Tuberculosis, Imaging, Chemistry	Design, synthesis and characterization of small molecule fluorophores as RNA mimics of green fluorescent protein for imaging purpose.
Tuberculosis, Target identification	BM212 drug target identification and validation: generation of resistant mutants, whole genome sequencing and development of assays that selectively access mycolates on the surface of *M. smegmatis* spheroplasts demonstrated that BM212 binds MmpL3 and inhibits flipping of mycolic acids across the inner membrane. PZP drug target identification and validation: generation of resistant mutants, whole genome sequencing, RNA extraction and quantitative RT-PCR, ESI-MS studies and UV-Vis titration of PZP with Fe^{2+} demonstrated that PZP enters mycobacterial cells and chelates Fe^{2+} and starves the bacteria for intracellular iron.
Leishmania, Medicinal chemistry	Design, synthesis and characterization of small molecules active against *Leishmania donovani.*
COX-2, Medicinal chemistry	Design, synthesis and characterization of small molecules endowed with nitric oxide releasing properties as analgesic/anti-inflammatory agents.
Asymmetric Synthesis, Lithium Amides	Asymmetric synthesis routes through doubly diastesreoselective addition of enantiopure lithium amides to enantiopure N-enoyl oxazolidin-2-ones.
Stereospecific Conversion, Olefin, Cyclic Carbonate	One-pot conversions of olefins to cyclic carbonates and secondary allylic and homoallylic amines to cyclic carbamates.

Part VIII – Summary of Scientific Achievements

VIIIA - Publications

Product type	Number	Data Base	Start	End
Papers	38	Scopus	2005	2018

Total Impact factor	140,712 (Journal citation reports)
Total Citations	880 (Scopus)
Average Citations per Product	23.16 (Scopus)
Hirsch (H) index	18 (Scopus)
Normalized H index	1.38

VIIIB - Conference communications

Product type	Number
Oral presentations [as invited speaker]	2
Seminars	2
Oral presentations	5
Posters	30

Part IX – Selected Publications with impact factor (Journal citation reports, 2017) **and citations** (Scopus)

1. **Poce, G.***; Cocozza, M.; Alfonso, S.; Consalvi, S.; Venditti, G.; Fernandez-Menendez, R.; Bates, R. H.; Barros Aguirre, D.; Ballell, L.; De Logu, A.; Vistoli, G.; Biava, M. In Vivo Potent BM635 Analogue with Improved Drug-Like Properties. *Eur. J. Med. Chem.* **2018**, *145*, 539-550. IF: 4.816, n. cit.: 1

2. Xua, Z.; Meshcheryakov, V. A.; **Poce, G.**; Chng, S. S. MmpL3 is the Flippase for Mycolic Acids in Mycobacteria. *PNAS* **2017**, *114*, 7993-7998. IF: 9.504, n. cit.: 13

3. **Poce, G**.*; Consalvi, S.; Cocozza, M.; Fernandez-Menendez, R.; Bates, R. H.; Ortega Muro, F.; Barros Aguirre, D.; Ballell, L.; Biava, M. Pharmaceutical Salt of BM635 with Improved Bioavailability. *Eur. J. Pharm. Sci.* **2017**, *99*, 17-23. IF: 3.466, n. cit.: 1

4. **Poce, G.***; Consalvi, S.; Biava, M. MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target. *Mini Rev. Med. Chem*. **2016**, *16*, 1274-1283. IF: 2.645, n. cit.: 6

5. Consalvi, S.; **Poce, G**.; Ragno, R.; Sabatino, M.; La Motta, C.; Sartini, S.; Calderone, V.; Martelli, A.; Ghelardini, C.; Di Cesare Mannelli, L.; Biava, M. A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis. *ChemMedChem.* **2016**, *11*, 1804-1811. IF: 3.009, n. cit.: 2

6. Di Capua, A.; Sticozzi, C.; Brogi, S.; Brindisi, M.; Cappelli, A.; Sautebin, L.; Rossi, A.; Pace, S.; Ghelardini, C.; Di Cesare Mannelli, L.; Valacchi, G.; Giorgi, G.; Giordani, A.; **Poce, G**.; Biava, M.; Anzini, M. Synthesis and Biological Evaluation of Fluorinated 1,5-Diarylpyrrole-3-Alkoxyethyl Ether Derivatives as Selective COX-2 Inhibitors Endowed with Anti-Inflammatory Activity. *Eur. J. Med. Chem.* **2016**, *109*, 99–106. IF: 4.816, n. cit.: 8

7. Consalvi, S.; Biava, M.; **Poce, G.** COX Inhibitors: A Patent Review (2011 – 2014). *Expert Opin. Ther. Pat.* **2015**, *25*, 1357-1371. IF: 2.867, n. cit.: 11

8. **Poce, G.**; Biava, M. Overcoming Drug Resistance for Tuberculosis. *Future Microbiol*. **2015**, *10*, 1735–1741. IF: 3.190, n. cit.: 5

9. Piccaro, G.; **Poce, G**.; Biava, M.; Giannoni, F.; Fattorini, L. Activity of Lipophilic and Hydrophilic Drugs Against Dormant and Replicating *Mycobacterium Tuberculosis*. *J. Antibiot*. **2015**, *68*, 711-714. IF: 2.033, n. cit.: 6

10. Dragset, M. S.; **Poce, G**.; Alfonso, S.; Padilla-Benavides, T.; Ioerger, T. R.; Kaneko, T.; Sacchettini, J. C.; Biava, M.; Parish, T.; Argüello, J. M.; Steigedal, M.; Rubin, E. J. A Novel Antimycobacterial Compound Acts as an Intracellular Iron Chelator. *Antimicrob. Agents Chemother.***2015**, *59*, 2256-2264. IF: 4.255, n. cit.: 6

11. Consalvi, S.; Alfonso, S.; Di Capua, A.; **Poce, G.**; Pirolli, A.; Sabatino, M.; Ragno, R.; Anzini, M.; Sartini, S.; La Motta, C.; Di Cesare Mannelli, L.; Ghelardini, C.; Biava, M. Synthesis, Biological Evaluation and Docking Analysis of a New Series of Methylsulfonyl and Sulfamoyl Acetamides and Ethyl Acetates as Potent COX-2 Inhibitors. *Bioorg. Med. Chem*. **2015**, *23*, 810–820. IF: 2.881, n. cit.: 13

12. **Poce, G.*;** Cocozza, M.; Consalvi, S.; Biava, M. SAR Analysis of New Anti-TB Drugs Currently in Pre-Clinical and Clinical Development. *Eur. J. Med. Chem*. **2014**, *86*, 335–351. IF: 4.816, n. cit.: 20

13. Biava, M.; Battilocchio, C.; **Poce, G**.; Alfonso, S.; Consalvi, S.; Di Capua, A.; Calderone, V.; Martelli, A.; Testai, L.; Sautebin, L.; Rossi, A.; Ghelardini, C.; Di Cesare Mannelli, L.; Giordani, A.; Persiani, S.; Colovic, M.; Dovizio, M.; Patrignani, P.; Anzini, M. Enhancing the Pharmacodynamic Profile of a Class of Selective COX-2 Inhibiting Nitric Oxide Donors. *Bioorg. Med. Chem.* **2014**, *22*, 772–786. IF: 2.881, n. cit.: 13

14. Martelli, A.; Testai, L.; Anzini, M.; Cappelli, A.; Di Capua, A.; Biava, M.; **Poce, G**.; Consalvi, S.; Giordani, A.; Caselli, G.; Rovati, L.; Ghelardini, C.; Patrignani, P.; Sautebin, L.; Breschi, M. C.; Calderone, V. The Novel Anti-Inflammatory Agent VA694, Endowed with Both NO-Releasing and COX2-Selective Inhibiting Properties, Exhibits NO-Mediated Positive Effects on Blood Pressure, Coronary Flow and Endothelium in an Experimental Model of Hypertension and Endothelial Dysfunction. *Pharmacol. Res.* **2013**, *78*, 1–9. IF: 4.897, n. cit.: 7

15. Baiocco, P.; **Poce, G**.; Alfonso, S.; Cocozza, M.; Porretta, G. C.; Colotti, G.; Biava, M.; Moraca, F.; Botta, M.; Yardley, V.; Fiorillo, A.; Lantella, A.; Malatesta, F.; Ilari, A. Inhibition of Leishmania Infantum Trypanothione Reductase by Azole-Based Compounds: A Comparative Analysis with Its Physiological Substrate by X-Ray Crystallography. *ChemMedChem* **2013**, *8*, 1175–1183. IF: 3.009, n. cit.: 26

16. Battilocchio, C.; **Poce, G**.; Alfonso, S.; Porretta, G. C.; Consalvi, S.; Sautebin, L.; Pace, S.; Rossi, A.; Ghelardini, C.; Di Cesare Mannelli, L.; Schenone, S.; Giordani, A.; Di Francesco, L.; Patrignani, P.; Biava, M. A Class of Pyrrole Derivatives Endowed with Analgesic/anti-Inflammatory Activity. *Bioorg. Med. Chem.* **2013**, *21*, 3695–3701. IF: 2.881, n. cit.: 25

17. Anzini, M.; Di Capua, A.; Valenti, S.; Brogi, S.; Rovini, M.; Giuliani, G.; Cappelli, A.; Vomero, S.; Chiasserini, L.; Sega, A.; **Poce, G**.; Giorgi, G.; Calderone, V.; Martelli, A.; Testai, L.; Sautebin, L.; Rossi, A.; Pace, S.; Ghelardini, C.; Di Cesare Mannelli, L.; Benetti, V.; Giordani, A.; Anzellotti, P.; Dovizio, M.; Patrignani, P.; Biava, M. Novel Analgesic/anti-Inflammatory Agents: 1,5-Diarylpyrrole Nitrooxyalkyl Ethers and Related Compounds as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. *J. Med. Chem.* **2013**, *56*, 3191–3206. IF: 6.253, n. cit.: 22

18. **Poce, G.***; Bates, R. H.; Alfonso, S.; Cocozza, M.; Porretta, G. C.; Ballell, L.; Rullas, J.; Ortega, F.; De Logu, A.; Agus, E.; La Rosa, V.; Pasca, M. R.; De Rossi, E.; Wae, B.; Franzblau, S. G.; Manetti, F.; Botta, M.; Biava, M. Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection. *PloS One* **2013**, *8*, e56980. IF: 2.766, n. cit.: 46

19. Biava, M.; Battilocchio, C.; **Poce, G**.; Alfonso, S.; Consalvi, S.; Porretta, G. C.; Schenone, S.; Calderone, V.; Martelli, A.; Testai, L.; Ghelardini, C.; Di Cesare Mannelli, L.; Sautebin, L.; Rossi, A.; Giordani, A.; Patrignani, P.; Anzini, M. Improving the Solubility of a New Class of Antiinflammatory Pharmacodynamic Hybrids, That Release Nitric Oxide and Inhibit Cycloxygenase-2 Isoenzyme. *Eur. J. Med. Chem.* **2012**, *58*, 287–298. IF: 4.816, n. cit.: 10

20. La Rosa, V.; **Poce, G**.; Canseco, J. O.; Buroni, S.; Pasca, M. R.; Biava, M.; Raju, R. M.; Porretta, G. C.; Alfonso, S.; Battilocchio, C.; Javid, B.; Sorrentino, F.; Ioerger, T. R.; Sacchettini, J. C.; Manetti, F.; Botta, M.; De Logu, A.; Rubin, E. J.; De Rossi, E. MmpL3 Is the Cellular Target of the Antitubercular Pyrrole Derivative BM212. *Antimicrob. Agents Chemother.* **2012**, *56*, 324–331. IF: 4.255, n. cit.: 121

Part X– Selected conference communications/seminars

XA - Oral communications/seminars

- Poce, G. Simple Chemistries as Enabling Tool for Advancing TB and Cancer Research. Department of Chemistry, University of Cape Town, Cape Town, South Africa, August 24, 2016. (Seminar)

- Poce, G. Towards Tuberculosis Treatment with Next Generation BM635 Analogues. NPCF8, Parma, June 09-11, 2014. (Oral Communication)

- Poce, G. Towards Tuberculosis Treatment with Novel MmpL3 Inhibitors. Dipartimento di Scienze Farmaceutiche, Università degli Studi di Perugia, Perugia, March 18, 2014. (Seminar)

- Poce, G. MmpL3 Inhibitors Enabling New Possibilities for TB Treatment. XXII National Meeting on Medicinal Chemistry, Rome, September 10-13, 2013. (Oral communication)

- Poce, G. BM212-Derived MmpL3 Inhibitors Enabling New Possibilities for the Treatment of TB. Tuberculosis Drug Development, Gordon Research Conference, Barga (LU), July 21-26, 2013. (Keynote_Invited speaker)

- Poce, G. Hit-to-Lead Development for a New Class of Anti-Mycobacterial Agents. Tres Cantos Open Lab Foundation, Tres Cantos, Spain, June 10, 2013. (Keynote_Invited speaker)

- Poce, G.; Porretta, G. C; De Logu, A.; De Rossi, E.; Rubin, E.J.; Ballel, L.; Botta, M.; Biava, M. 1,5-Diphenyl Pyrrolesas New Antimycobacterial Agents. Hit-to-lead Development and Target Validation. COST Action MeetingCM0801, Siena, May 30 – June 5, 2012. (Short oral communication)

- Poce, G. Identification of a New Chemical Series of Potent Antimycobacterial Compounds. XX National Meeting on Medicinal Chemistry, Abano Terme, September 12-16, 2010. (Oral communication)

- Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Manetti, F.; Botta, M. New Pyrrole Derivatives of BM212: a New Class of Antimycobacterial Agents. Design, Synthesis, Biological Evaluation and Study of Their Mode of Action. NPCFIII, Pisa, February 13-14, 2009. (Oral communication)

XB - Poster communications:

- Poce, G.; Venditti, G.; Consalvi, S.; De Logu, A.; Boshoff, H.; Rubin, E. J.; Biava, M. Anthranilate-Like Inhibitors as Potent Antitubercular Agents. Tuberculosis Drug Development, Gordon Research Conference, Barga (LU), July 25-30, 2017.

- Poce, G.; Consalvi, S.; Alfonso, S.; Fernandez-Menendez, R.; Bates, R. H.; Ballell, L.; Biava, M. Pyrazole Analogs of BM635 as Potent Antimycobacterial Agents. Tuberculosis Drug Development, Gordon Research Conference, Barga (LU), July 12-17, 2015.

- Poce, G.; Biava, M.; Porretta, G.C.; Battilocchio, C.; Alfonso, S.; Botta, M.; Javid, B.; Sorrentino, F.; Ioerger, T.R.; Sacchettini, J.R.; Rubin, E. BM212 Targets MmpL3.Tuberculosis Drug Development, Gordon Research Conference, Barga (LU), July 4-8, 2011.

- Biava, M.; Porretta, G.C.; Poce, G.; Alfonso, S.; Battilocchio, C.; De Logu, A.; Manetti, F.; Botta, M. BM579: a Novel Pyrrole Derivatives with Improved Antimycobacterial Activity. IV Meeting NPCF, Santa Margherita di Pula, May 6-7, 2010.

- Biava, M.; Porretta, G.C.; Poce, G.; Battilocchio, C.; Alfonso, S.; De Logu, A.; De Rossi, E.; Manetti, F.; Botta, M. New Pyrrole Derivatives of BM212: a New Class of Antimycobacterial Agents. Design, Synthesis, Biological Evaluation and Study of Their Mode of Action. Cost Action Meeting (CM0801-New Drugs for Neglected Diseases), Certosa di Pontignano, Siena, May 28-29, 2010.

- Poce, G.; Biava, M.; Porretta, G. C. Microwave Assisted Synthetic Pathways, a Rapid Approach to Obtain Substituted Pyrroles and Imidazoles as Antimycobacterial and Anti-Inflammatory Agents. Zing – Microwave and Flow Chemistry Conference. Antigua, January 28-31, 2009.

- Poce, G.; Porretta, G. C.; De Logu, A.; De Rossi, E.; Manetti, F.; Botta, M.; Biava, M. BM212 and its Derivatives: Lead Optimization of a New Class of Antimycobacterial Agents. "Cost Action", Rauischholzhausen Castle, Germany, March 19-21, 2009.

- Biava, M.; Porretta, G.C.; Battilocchio, C.; Poce, G.; De Logu, A.; Manetti, F.; Botta, M. Pyrrole Derivatives of BM212 as Novel Antimycobacterial Agents. Design, Synthesis, Biological Evaluation and Study of their Mode of Action. XXVIII Convegno Nazionale SIMGBM, della Società italiana di Microbiologia Generale e Biotecnologie Microbiche, Spoleto, June 11-13, 2009.

- Poce, G.; Porretta, G. C.; Borzi, F.; De Logu, A.; De Rossi, E.; Manetti, F.; Botta, M.; Biava, M. New Pyrrole Derivatives of BM212: Lead Compound Optimization Strategy. Tuberculosis drug development. Targets, technologies and trials, Magdalen College, Oxford, United Kingdom, August 16-21, 2009.

- Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Maleddu, R.; De Rossi, E.; Manetti, F.; Botta, M. Design and Synthesis of 1,5-Diaryl-2-Ethyl Pyrrole Derivatives and their Evaluation as Antimycobacterial Agents. XIX National Meeting on Medicinal Chemistry Division of Italian Chemical Society (SCI), Verona, September 14-18, 2008.

- Poce, G.; Porretta, G.C.; Borzi, F.; De Logu, A.; De Rossi, E.; Manetti, F.; Botta, M.; Biava, M. BM212 and New Derivatives as a New Class of Antimycobacterial Agents. First IRBM workshop on Medicinal & Organic Chemistry. Pomezia (RM), September 26, 2008.

- Biava, M.; Porretta, G.C.; Poce, G.; Deidda, D.; Pompei, R.; Manetti, F.; Botta, M. Design, Synthesis and Screening of New Antitubercular Agents Derived from BM212. VI Laboratorio di Metodologie Sintetiche in Chimica Farmaceutica. Siena, February 11-16, 2007.

- Poce, G. Synthesis of New Pyrrole Derivatives of BM212, a Potent Antimycobacterial Compound. European School of Medicinal Chemistry (ESMEC), July 1-6, 2007.

- Biava, M.; Porretta, G.C.; Poce, G.; De Logu, A.; Manetti, F.; Botta, M. New 1,5-diphenyl Pyrrole Derived from BM212: a New Class of Antimycobacterial Agents. Tuberculosis Drug Development. Gordon Research Conference, Oxford, August 26-31, 2007.

- Biava, M.; Porretta, G.C.; Poce, G.; Supino, G.; Deidda, D.; Pompei, R.; Manetti, F.; Botta, M. Synthesis of New Pyrrole Derivatives of BM212, a Potent Antimycobacterial Compound, XXII Congresso Nazionale della Società Chimica Italiana, Firenze, September 10-15, 2006.

- Biava, M.; Porretta, G.C.; Poce, G.; Deidda, D.; Pompei, R.; Tafi, A.; Manetti, F. Nuovi Derivati 1,5-Difenilpirrolici Derivati del BM212 Attivi come Agenti Antitubercolari. XVII National Meeting of Medicinal Chemistry Division of Italian Chemical Society (SCI), Pisa, September 6-10, 2004.

Part XI – Other Scientific Achievements

XIA - Invitation for writing review and perspectives:

- Poce, G.; Consalvi, S.; Biava, M. MmpL3 Inhibitors: Diverse Chemical Scaffolds Inhibit the Same Target. *Mini Rev. Med. Chem*. **2016**, *16*, 1274-1283.
- Poce, G.; Biava, M. Overcoming Drug Resistance for Tuberculosis. *Future Microbiol*. **2015**, *10*, 1735–1741.
- Poce, G.; Porretta, G. C.; Biava, M. C-9 Alkenylidine Bridged Macrolides: WO2008061189. Enanta Pharmaceuticals, Inc. *Expert Opin. Ther. Pat.* **2009**, *19*, 901-6.

XIB - Session Chairman:

Session: Alternative Approaches to Target ID and Drug Discovery. Tuberculosis Drug Development, Gordon-Kenan Research Seminar, Barga (LU), July 20-21, 2013.

XIC - Editorial Board Member

Editorial board member of Annals of Medicinal Chemistry and Research

XID - Peer reviewer for international journals:

- Journal of Medicinal Chemistry
- ACS Medicinal Chemistry Letters
- ChemMedChem
- Expert Opinion on Therapeutic Targets
- Journal of Pharmacy and Pharmacology
- Molecules

XIE - Collaborations:

- Eric J. Rubin, Department of Immunology and Infectious Diseases, Harvard School of Public Health, USA
- Lluis Ballell, Tres Cantos Medicines Development Campus, GlaxoSmithKline, Tres Cantos, Spain.
- Celia Goulding, Fort Collins, University of California, Irvine, US.
- Chng Shu Sin, National University of Singapore, Singapore, Republic of Singapore.
- Musa Mhlanga, Faculty of Health Sciences, University of Cape Town, South Africa.
- Kelly Chibale, Department of Chemistry, University of Cape Town, South Africa.

Roma, 06/08/2018

Giovanna Poce